KEYNOTE-522 · 2020 · New England Journal of Medicine
Pembrolizumab for Early Triple-Negative Breast Cancer
Neoadjuvant pembrolizumab + chemotherapy increases pathologic complete response rate in triple-negative breast cancer.
Source publication
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al. · New England Journal of Medicine · 2020
Sponsor
Merck Sharp & Dohme LLC
Principal investigator
Medical Director
Population
Triple Negative Breast Neoplasms; n=1174
Primary endpoint
Pathological complete response (pCR) rate using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) at the time of definitive surgery
Methodology notes
Full methodology is under curation. This project aggregates 3 seeded claims across three temporal layers. The replication spec, pre-registered analysis, and version history will appear here as the project matures.
Funding progress
$1.3M / $3.9M
32%
Funding displayed here is indicative of collaborator interest. Sciync does not broker money, grants, or securities.
Temporal layers
Published findings under validation
1
Active replication in progress
1
Forecast horizons pending resolution
1